Posted by Michael Wonder on 14 Jul 2023
TheracosBio announces commercial availability of Brenzavvy (bexagliflozin) for the treatment of adults with type 2 diabetes
13 July 2023 - Distribution through Mark Cuban Cost Plus Drug Company introduces affordably priced SGLT2 inhibitors.
TheracosBio today announced that Brenzavvy (bexagliflozin), an FDA approved oral sodium-glucose co-transporter 2 inhibitor, is now available by prescription through the Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs).
